Role of vitamins and minerals in prevention and management of type 2 diabetes mellitus

Nutrition Reviews

Volumn 68, Issue 6, 2010, Pages 341-354

  Martini, Lígia A ^a   Catania, Antonela S ^a   Ferreira, Sandra R G ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Diabetic complications; Diet; Glycemic control; Insulin resistance; Micronutrients; Type 2 diabetes mellitus

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALDOSTERONE; ALPHA TOCOPHEROL; ASCORBIC ACID; BETA CAROTENE; BIOTIN; CALCIUM; CYANOCOBALAMIN; FOLIC ACID; GLUCOSE; GLUCOSE TRANSPORTER 4; HOMOCYSTEINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAGNESIUM; NICOTINAMIDE; PANTOTHENIC ACID; PLACEBO; POTASSIUM; PREALBUMIN; PYRIDOXINE; RETINOL; RETINOL BINDING PROTEIN 4; RIBOFLAVIN; SELENIUM; SODIUM; THIAMINE; UNINDEXED DRUG; VITAMIN B COMPLEX; VITAMIN D; VITAMIN K GROUP; ALKALI METAL; ALKALINE EARTH METAL; VITAMIN;

ALCOHOL CONSUMPTION; AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; BLOOD PRESSURE; BODY MASS; BRAIN ISCHEMIA; BREAD; CALCIUM HOMEOSTASIS; CALCIUM METABOLISM; CAUSE OF DEATH; CELL GROWTH; CELL PROLIFERATION; CELL SECRETION; CLINICAL TRIAL; COFFEE; DIABETIC HYPERTENSION; DIABETIC NEUROPATHY; DRUG MEGADOSE; EDUCATIONAL STATUS; ENERGY YIELD; FAT INTAKE; FOOD INTAKE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLUCOSE OXIDATION; GRAIN; HEART DEATH; HEART INFARCTION; HEMODYNAMICS; HORMONE SYNTHESIS; HUMAN; HYPERGLYCEMIA; HYPERHOMOCYSTEINEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; INSULIN RESISTANCE; LEAFY VEGETABLE; LIPID ANALYSIS; MEAT; MICROALBUMINURIA; MINERAL INTAKE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUT; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; RECEPTOR UPREGULATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; SMOKING; SMOOTH MUSCLE FIBER; SODIUM INTAKE; STROKE; THERMOGENESIS; THROMBOCYTE ADHESIVENESS; VITAMIN DEFICIENCY; VITAMIN SUPPLEMENTATION; WEIGHT REDUCTION; ANIMAL; DIET SUPPLEMENTATION; METABOLISM; NUTRITIONAL DEFICIENCY;

ANIMALS; DEFICIENCY DISEASES; DIABETES MELLITUS, TYPE 2; DIETARY SUPPLEMENTS; GLUCOSE; HUMANS; METALS, ALKALI; METALS, ALKALINE EARTH; VITAMINS;

EID: 77956629251     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1111/j.1753-4887.2010.00296.x     Document Type: Review

References (127)

1. Zimmet P, Alberti KGMM, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782-787.
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053.
3. Marshall JA, Hoag S, Shetterly S, Hamman RF. Dietary fat predicts conversion from impaired glucose tolerance to NIDDM. Diabetes Care. 1994;17:50-56.
4. Meyer KA, Kushi LH, Jacobs DR Jr, Slavin J, Sellers TA, Folsom AR. Carbohydrates, dietary fiber, and incident type 2 diabetes in older women. Am J Clin Nutr. 2000;71:921-930.
5. Van Dam RM, Willett WC, Rimm EB, Stampfer MJ, Hu FB. Dietary fat and meat intake in relation to risk of type 2 diabetes in men. Diabetes Care. 2002;25:417-424.
6. Schulze MB, Liu S, Rimm EB, Manson JE, Willett WC, Hu FB. Glycemic index, glycemic load, and dietary fiber intake and incidence of type 2 diabetes in younger and middle-aged women. Am J Clin Nutr. 2004;80:348-356.
7. Liu S, Serdula M, Janket S-J, et al. A prospective study of fruit and vegetable intake and the risk of type 2 diabetes in women. Diabetes Care. 2004;27:2993-2996.
8. Tinker LF, Bonds DE, Margolis KL, Manson JE, Howard BV, et al. Low-fat dietary pattern and risk of treated diabetes mellitus in postmenopausal women. The Women's Health Initiative Randomized Controlled Dietary Modification Trial. Arch Intern Med. 2008;168:1500-1511.
9. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350.
10. Knowler WC, Barrett-Connor E, Fowler SE, et al. for the Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
11. American Diabetes Association. Nutrition recommendations and interventions for diabetes. A position statement of the American Diabetes Association. Diabetes Care. 2008; 31(Suppl 1):S61-S78.
12. Feskens EJ, Virtanen SM, Rasanen L, et al. Dietary factors determining diabetes and impaired glucose tolerance: A 20-year follow-up of the Finnish and Dutch cohorts of the Seven Countries Study. Diabetes Care. 1995;18:1104-1112.
13. Will JC, Ford ES, Bowman BA. Serum vitamin C concentrations and diabetes: Findings from the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Clin Nutr. 1999;70:49-52.
14. Ford ES, Mokdad AH. Fruit and vegetable consumption and diabetes mellitus incidence among US adults. Prev Med. 2001;32:33-39.
15. Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes: A systematic review and meta-analysis. J Clin Endocrinol Metab. 2007;92:2017-2029.
16. Kadowaki S, Norman AW. Dietary vitamin D is essential for normal insulin secretion from the perfused rat pancreas. J Clin Invest. 1984;73:759-766.
17. Beaulieu C, Kestekian R, Havrankova J, Gascon-Barre M. Calcium is essential in normalizing intolerance to glucose that accompanies vitamin D depletion in vivo. Diabetes. 1993;42:35-43.
18. Maestro B, Campion J, Davila N, Calle C. Stimulation by 1,25- dihydroxyvitamin D3 of insulin receptor expression and insulin responsiveness for glucose transport in U-937 human promonocytic cells. Endocr J. 2000;47:383-391.
19. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes and cardiovascular disease? The common hypothesis revisited. Arterioscler Thromb Vasc Biol. 2004;24:816-823.
20. Wen Y, Skidmore JC, Porter-Turner MM, et al. Relationship of glycation, antioxidant status and oxidative stress to vascular endothelial damage in diabetes. Diabetes Obes Metab. 2002;4:305-308.
21. deBoer IH, Tinker LF, Connelly S, Curb JD, Howard BV, et al. Calcium plus vitamin D supplementation and the risk of incident diabetes in theWomen's Health Initiative. Diabetes Care. 2008;31:701-707.
22. Saw SM, Yuan JM, Ong CN, Arakawa K, Lee HP, Coetzee GA. Genetic, dietary and other lifestyle determinants of plasma homocysteine concentrations in middle-aged and older Chinese men and women in Singapore. Am J Clin Nutr. 2001;73:232-239.
23. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocysteine and risk ofmyocardial infarction in US physicians. JAMA. 1992;268:877-881.
24. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total concentration of homocysteine and risk of stroke in middle-aged British men. Lancet. 1995;346:1395-1398.
25. Verhoef P, Kok FJ, Kruyssen DACM, et al. Plasma total homocysteine, B vitamin and risk of coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 1997;17:989-995.
26. The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: A metaanalysis. JAMA. 2002;288:2015-2022.
27. Anderson JL, Muhlesteim JB, Horne BD, et al. Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation. 2000;102:1227-1232.
28. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: Evidence on causality froma meta-analysis. BMJ. 2002;325:1-7.
29. Potter K, Hankey GJ, Green DJ, Eikelboom J, Jamrozik K, Arnolda LF. The effect of long-term homocysteine-lowering on carotid intima-media thickness and flow-mediated vasodilation in stroke patients: A randomized controlled trial and meta-analysis. BMC Cardiovasc Disord. 2008;20:8-24.
30. Hodis HN, Mack WJ, Dustin L, et al. High-dose B vitamin supplementation and progression of subclinical atherosclerosis. A randomized controlled trial. Stroke. 2009;40:730-736.
31. Wald DS, Morris JK, Law M, Wald NJ. Folic acid, homocysteine, and cardiovascular disease: Judging causality in the face of inconclusive trial evidence. BMJ. 2006;333:1114-1117.
32. Munshi M, Stone A, Fink L, Fonseca V. Hyperhomocysteinemia following a methionine load in patients with noninsulin- dependent diabetes mellitus and macrovascular disease. Metabolism. 1996;45:133-135.
33. Chico A, Perez A, Cordoba , Arcelus R, et al. Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: A new link between diabetic nephropathy and cardiovascular disease? Diabetologia. 1998;41:684-693.
34. Smulders Y, Rakic M, Slaats E, et al. Fasting and posmethionine homocysteine levels in NIDDM: Determinants and correlations with retinopathy, albuminuria and cardiovascular disease. Diabetes Care. 1999;22:125-132.
35. Buysschaert M, Dramais A-S, Wallemacq PE, Hermans MP. Hyperhomocysteinemia in type 2 diabetes. Relationship to macroangiopathy, nephropathy, and insulin resistance. Diabetes Care. 2000;23:1816-1822.
36. Davies L, Wilmshurst EG, McElduff A, Gunton J, Clifton-Bligh P, Fulcher GR. The relationship among homocysteine, creatinine clearance, and albuminuria in patients with type 2 diabetes. Diabetes Care. 2001; 24:1805-1809.
37. Hu FB, Stampfer MJ, Solomon CG, et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med. 2001;161:1717-1723.
38. Fonseca V, Desouza C, Asnani S, Jialal I. Nontraditional risk factors for cardiovascualr disease in diabetes. Endocr Rev. 2004;25:153-175.
39. Hoogeveen E, Kostense PJ, Beks PJ, et al. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: A population-based study. Arterioscler Thromb Vasc Biol. 1998;18:133-138.
40. Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of cardiovascular diseases: A metaanalysis of randomized controlled trials. JAMA. 2006;296:2720-2726.
41. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: The Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291:565-575.
42. Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354:1578-1588.
43. Lonn E, Yusuf S, Arnold MJ, et al. The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354:1567-1577.
44. Lanfredini M, Fiorina P, Peca MG, et al. Fasting and postmethionine load homocyst(e)ine values are correlated with microalbuminuria and could contribute to worsening vascular damage in non-insulin-dependent diabetes mellitus patients. Metabolism. 1998;47:915-921.
45. Wollesen F, Brattstrom L, Refsum H, Ueland P, Berglund L, Berne C. Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. Kidney Int. 1999;55:1028-1035.
46. Sun Y, Lai MS, Lu CJ. Effectiveness of vitamin B12 on diabetic neuropathy: Systematic review of clinical controlled trials. Acta Neurol Taiwan. 2005;14:48-54.
47. Ang CD, Alviar MJ, Dnas AL, et al. Vitamin B for treating peripheral neuropathy. Cochrane Database Syst Rev. 2008;16:CD04573.
48. Neri S, Bruno CM, Raciti C, et al. Alteration of oxide reductive and haemostatic factors in type 2 diabetics. J Intern Med. 1994;236:495-500.
49. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care. 1996;19:257-267.
50. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-820.
51. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress activated signaling pathways: A unifying hypothesis of type 2 diabetes. Endocr Rev. 2002;23:599-622.
52. Diaz MN, Frei B, Vita JA, Keaney JF Jr. Antioxidants and atherosclerotic heart disease. N Engl J Med. 1997;337:408-416.
53. Jha P, Flather M, Lonn E, et al. The antioxidant vitamins and cardiovascular disease. A critical review of epidemiologic and clinical trial data. Ann Intern Med. 1995;123:860.
54. Basu TK, Basualdo C. Vitamin A homeostasis and diabetes mellitus. Nutrition. 1997;13:804-806.
55. Basualdo CG, Wein EE, Basu TK. Vitamin A (retinol) status of First Nation adults with non-insulin dependent diabetes mellitus. J Am Coll Nutr. 1997;16:39-45.
56. Yang Q, Graham TE, Mody N, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature. 2005;436:729-733.
57. Graham TE, Yang Q, Bluher M, et al. Retinol-binding protein 4 and insulin resistance in lean, obese and diabetic subjects. N Engl J Med. 2006;354:2552-2563.
58. Akbaraly TN, Fontbonne A, Favier A, Berr C. Plasma carotenoids and onset of dysglycemia in an elderly population: Results of the epidemiology of vascular ageing study. Diabetes Care. 2008;31:1355-1359.
59. Czernichow S, Couthouis A, Bertrais S, et al. Antioxidant supplementation does not affect fasting plasma glucose in the supplementation with antioxidant vitamins and minerals (SU.VI.MAX) study in France: Association with dietary intake and plasma concentrations. Am J Clin Nutr. 2006; 84:395-399.
60. Nwose EU, Jelinek HF, Richards RS, Kerr PG. The vitamin E regeneration system' (VERS) and an algorithm to justify antioxidant supplementation in diabetes - a hypothesis. Med Hypotheses. 2008;70:1002-1008.
61. Shirpoor A, Salami S, Khadem-Ansari MH, Ilkhanizadeh B, Pakdel FG, Khademvatani K. Cardioprotective effect of vitamin E: Rescues of diabetes-induced cardiac malfunction, oxidative stress, and apoptosis in rat. J Diabetes Complic. 2009;23:310-316.
62. Sena CM, Nunes E, Gomes A, et al. Supplementation of coenzyme Q10 and alpha-tocopherol lowers glycated hemoglobin level and lipid peroxidation in pancreas of diabetic rats. Nutr Res. 2008;28:113-121.
63. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med. 1993;328:1444-1449.
64. RimmEB, Stampfer MJ, Ascherio A, Giovannuci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med. 1993;328:1450-1456.
65. Lonn E, Yusuf S, Hoogwerf B, et al. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes. Diabetes Care. 2002;25:1919-1927.
66. Liu S, Lee I-M, Song Y, et al. Vitamin E and risk of type 2 diabetes in the Women's Health Study randomized controlled trial. Diabetes. 2006;55:2856-2862.
67. Ward NC, Wu Jason HY, Clarke MW, et al. The effect of vitamin E on blood pressure in individuals with type 2 diabetes: A randomized, double-blind, placebo-controlled trial. J Hypertens. 2007;25:227-234.
68. Miller ER III, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: High dosage vitamin E supplementation may increase all cause mortality. Ann Intern Med. 2005;142:37-46.
69. Halliwell B. How to characterize an antioxidant: An update. In: Rice-Evans C, Halliwell B, Lunt GG, eds. Free Radicals and Oxidative Stress: Environment, Drugs and Food Additives. London: Portland Press; 1995:73-101.
70. Halliwell B. Vitamin C: Antioxidant or pro-oxidant in vivo? Free Radic Res. 1996;25:439-454.
71. Podmore ID, Griffiths HR, Herbert KE, Mistry N, Mistry P, Lunec J. Vitamin C exhibits pro-oxidant properties. Nature. 1998;392:559.
72. Lee KW, Mossine V, Ortwerth BJ. The relative ability of glucose and ascorbate to glycate and crosslink lens proteins in vitro. Exp Eye Res. 1998;67:95-104.
73. Harding A, Wareham NJ, Bingham SA, et al. Plasma vitamin C level, fruit and vegetable consumption, and the risk of new-onset type 2 diabetes mellitus. The European Prospective Investigation of Cancer-Norfolk Prospective Study. Arch Intern Med. 2008;168:1493-1499.
74. Ford ES, Mokdad AH, Giles WH, Brown DW. The metabolic syndrome and antioxidant concentrations: Findings from the Third National Health and Nutrition Examination Survey. Diabetes. 2003;52:2346-2352.
75. Sinclair AJ, Taylor PB, Lunec J, Girling AJ, Barnett AH. Low plasma ascorbate levels in patients with type 2 diabetes mellitus consuming adequate dietary vitamin C. Diabet Med. 1994;11:893-898.
76. Paolisso G, Balbi V, Volpe C, et al. Metabolic benefits deriving from chronic vitamin C supplementation in aged noninsulin- dependent diabetics. J Am Coll Nutr. 1995;14:387-392.
77. Regensteiner JG, Popylisen S, Bauer TA, et al. Oral L-arginine and vitamins E and C improve endothelial function in women with type 2 diabetes. Vasc Med. 2003;8:169-175.
78. Chen H, Karne RJ, Hall G, et al. High-dose oral vitamin C partially replenishes vitamin C levels in patients with type 2 diabetes and low vitamin C levels but does not improve endothelial dysfunction or insulin resistance. Am J Physiol Heart Circ Physiol. 2006;290:H137-H145.
79. Beckman JA, Goldfine AB, Gordon MB, Garrett LA, Keaney Jr JF, CreagerMA. Oral antioxidant therapy improves endothelial function in type 1 but not type 2 diabetes mellitus. Am J Physiol Heart Circ Physiol. 2003;285:H2392-H2398.
80. Darko D, Dornhorst A, Kelly FJ, Ritter JM, Chowienczyk PJ. Lack of effect of oral vitamin C on blood pressure, oxidative stress and endothelial function in type II diabetes. Clin Sci. 2002;103:339-344.
81. Lee DH, Folsom AR, Harnack L, Halliwell B, Jacobs Jr DR. Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes? Am J Clin Nutr. 2004;80:1194-1200.
82. Bouillon R, Carmeliet G, Verlinden L, et al. Vitamin D and human health: Lessons from vitamin D receptor null mice. Endocr Rev. 2008;29:726-776.
83. Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr. 2004;79:820-825.
84. Chiu KC, Chuang LM, Yoon C. The vitamin D receptor polymorphism in the translation initiation codon is a risk factor for insulin resistance in glucose tolerant Caucasians. BMC Med Genet. 2001;2:2.
85. Sergeev IN, Rothen WB. 1,25-dihydroxivitamin D3 evokes oscillations of intracellular calcium in a pancreatic ß-cell line. Endocrinology. 1995;136:2852-2861.
86. Palomer X, Gonzalez-Clemente JM, Blanco-Vaca F, Mauricio D. Role of vitamin D in the pathogenesis of type 2 diabetes mellitus. Diabetes Obes Metab. 2008;10:185-197.
87. Norman AW, Frankel JB, Heldt AM, Grodsky GM. Vitamin D deficiency inhibits pancreatic secretion of insulin. Science. 1980;209:823-825.
88. Zeitz U, Weber K, Soegiarto DW, et al. Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. FASEB J. 2003;17:509-511.
89. Cade C, Norman AW. Rapid normalization/stimulation by 1,25-dihydroxyvitamin D3 of insulin secretion and glucose tolerance in the vitamin D-deficient rat. Endocrinology. 1987;120:1490-1497.
90. Anastasilakis AD, Efstathiadou Z, Plevraki E, et al. Effect of exogenous intermittent recombinant human PTH 1-34 administration and chronic endogenous parathyroid hormone excess on glucose homeostasis and insulin sensitivity. Horm Metab Res. 2008;40:702-707.
91. Zemel M, Thompson W, Milstead A, et al. Calcium and dairy acceleration of weight and fat loss during energy restriction in obese adults. Obes Res. 2004;12:582-590.
92. Zemel MB, Donnelly JE, Smith BK, et al. Effects of dairy intake on weight maintenance. Nutr Metab. 2008;5:28.
93. Zemel MB, Sun X. Calcitrol and energy metabolism. Nutr Rev. 2008;66(Suppl 2):S139-S146.
94. Lanou AJ, Barnard ND. Dairy and weight loss hypothesis: An evaluation of the clinical trials. Nutr Rev. 2008;66:272-279.
95. Sneeve M, Figenschau Y, Jorde R. Supplementation with cholecalciferol does not result in weight reduction in overweight and obese subjects. Eur J Endocrinol. 2008;159:675-684.
96. Pittas AG, Dawson-Hughes B, Li T, et al. Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care. 2006;29:650-656.
97. Pittas AG, Harris SS, Stark PC, Dawson-Hughes B. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes Care. 2007;30:980-986.
98. Sakamoto N, Nishiike T, Iguchi H, Skamoto K. Relationship between acute insulin response and vitamin K intake in healthy young male volunteers. Diabetes Nutr Metab. 1999;12:37-41.
99. Sakamoto N, Nishiike T, Iguchi H, Sakamoto K. Possible effects of one week vitamin K (menaquinone-4) tablets intake on glucose tolerance in healthy young male volunteers with different descarboxy prothrombin levels. Clin Nutr. 2000;19:259-263.
100. Yoshida M, Jacques PJ, Meigs JB, et al. Effect of vitamin K supplementation on insulin resistance in older men and women. Diabetes Care. 2008;31:2092-2096.
101. Horiuchi T, Kazama K, Araki A, et al. Impaired gamma carboxylation of osteocalcin in elderly women with type 2 diabetes mellitus: Relationship between increase in undercarboxylated osteocalcin levels and low bone mineral density. J Bone Miner Metab. 2004;22:236-240.
102. Ferron M, Hinoi E, Karsenty G, Ducy P. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci. 2008;105:5266-5270.
103. Ohsaki Y, Shirakawa H, Hiwatashi K, et al. Vitamin K suppresses lipopolysaccharide-induced inflammation in the rat. Biosci Biotechnol Biochem. 2006;70:926-932.
104. Shea MK, Booth SL, Massaro JM, et al. Vitamin K and vitamin D status: Associations with inflammatory markers in the Framingham Offspring Study. Am J Epidemiol. 2008;167: 313-320.
105. Barbagallo M, Dominguez LJ, Galioto A, et al. Role of magnesium in insulin action, diabetes and cardio-metabolic syndrome X. Mol Aspects Med. 2003;24:39-52.
106. Sales CH, Pedrosa Lde F. Magnesium and diabetes mellitus: Their relation. Clin Nutr. 2006;25:554-562.
107. Lopez-Riadura R, Willett WC, Rimm EB, et al. Magnesium intake and risk of type 2 diabetes in men and women. Diabetes Care. 2004;27:134-140.
108. Rodriguez-Morán M, Guerrero-Romero P. Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: A randomized double-blind controlled trial. Diabetes Care. 2003;26:1147-1152.
109. Song Y, Heg K, Levitan EB, Mason JE, Liu S. Effects of oral magnesium supplementation on glycaemic control in type 2 diabetes: A meta-analysis of a meta-analysis of randomized double-blind controlled trials. Diabet Med. 2006;23: 1050-1056.
110. Townsend RR, Zhao H. Plasma renin activity and insulin sensitivity in normotensive subjects. Am J Hypertens. 1994;7: 894-898.
111. Townsend RR, Kapoor S, McFadden CB. Salt intake and insulin sensitivity in healthy human volunteers. Clin Sci. 2007;113:141-148.
112. Lastra-Lastra G, Sowers JR, Restrepo-Erazo K, Manrique-Acevedo C, Lastra-González G. Role of aldosterone and angiotensin II in insulin resistance: An update. Clin Endocrinol. 2009;71:1-6.
113. Hu G, Jousilahti P, Peltonen M, Lindström J, Tuomilehto J. Urinary sodium and potassium excretion and the risk of type 2 diabetes: A prospective study in Finland. Diabetologia. 2005;48:1477-1483.
114. Colditz GA, Manson JE, Stampfer MJ, Rosner B, Willett WC, Speizer FE. Diet and the risk of clinical diabetes in women. Am J Clin Nutr. 1992;55:1018-1023.
115. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: A network meta-analysis. Lancet. 2007;369:201-207.
116. Zillich AJ, Garg J, Basu J, Barkis GL, Carter BL. Thiazide diuretics, potassium, and the development of diabetes: A quantitative review. Hypertension. 2006;48:219-224.
117. Rowe JW, Tobin JD, Rosa RM, Andres R. Effect of experimental potassium deficiency on glucose and insulin metabolism. Metabolism. 1980;29:498-502.
118. Vallotton MB, Rossier MF, Capponi AM. Potassiumangiotensin interplay in the regulation of aldosterone biosynthesis. Clinical Endocrinol. 1995;42:111-119.
119. Ogihara T, Asano T, Ando K, et al. Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension. 2002;40:872-879.
120. Hansson L, Lindhon LH, Niskanen L, et al. Effect of angiotensin- converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomized trial. Lancet. 1999;353:611-616.
121. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
122. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular mortality in the Losartan Intervention for Endpoint Reduction in Hypertension study (LIFE): A randomized trial against atenolol. Lancet. 2002;359:995-1003.
123. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlopidine: The VALUE randomized trial. Lancet. 2004;363:2022-2031.
124. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab. 2004;30:487-496.
125. Bosch J, Yusuf S, Gerstein HC, et al. DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355:1551-1562.
126. Hasanain B, Mooradian AD. Antioxidant vitamins and their influence in diabetes mellitus. Curr Diab Rep. 2002;2:448-456.
127. Department of Health and Human Services (HHS) and the US Department of Agriculture (USDA). Dietary Guidelines for Americans. 2005; Available at: Http://www.health.gov/Dietaryguidelines/dga2005/document/default.htm. Accessed 23 April 2010.